Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62430 | 0.84 | CA9 (0.46) | GPR3CA1CA2CA9MEN1 | |
| SCHEMBL31003510 | 0.84 | CA9 (0.46) | GPR3CA1CA2CA9MEN1 | |
| Water SCHEMBL27659746 | 0.82 | CA9 (0.44) | GPR3CA1CA2CA9MEN1 | |
| Methoxymethane SCHEMBL10856175 | 0.77 | CA9 (0.41) | GPR3CA1CA2CA9MEN1 | |
| Thiophene SCHEMBL28465488 | 0.74 | MEN1 (0.42) | GPR3CA1CA2CA9MEN1 | |
| Acetone SCHEMBL8996477 | 0.74 | CA9 (0.39) | GPR3CA1CA2CA9MEN1 | |
| SCHEMBL11036902 | 0.69 | GPR3 (0.55) | GPR3CA1CA2CA9MEN1 | |
| SCHEMBL2376272 | 0.69 | GPR3 (0.42) | GPR3CA1CA2CA9MEN1 | |
| SCHEMBL19744948 | 0.68 | GPR3 (0.48) | GPR3CA1CA2CA9MEN1 | |
| Cyclohexylamine SCHEMBL4918979 | 0.67 | CA1 (0.37) | CA1CA2CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060062862-A1 | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances | NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) | 2006-03-23 | — | — | US | claimed |
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CYTODYN INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4090675-A1 | CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC CANCER | CytoDyn Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220298249-A1 | METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | CYTODYN INC (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4007603-A1 | METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | CytoDyn Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220162327-A1 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | CYTODYN INC (US) | 2022-05-26 | — | — | US | disclosed |
| CN-114502594-A | Methods for treating or preventing cancer involving administration of anti-CCR5 receptor agents | 西托戴恩股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3947431-A1 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | CytoDyn Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021146323-A1 | CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC BREAST CANCER | CYTODYN INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210214448-A1 | CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER | CYTODYN INC. | 2021-07-15 | — | — | US | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-2000001687-A1 | BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE & CO. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999064410-A1 | BENZO(b)THIEPINE-1,1-DIOXIDE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064409-A2 | BENZOTHIEPINE-1,1-DIOXIDE DERIVATIVES, METHOD FOR PRODUCING THEM, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-12-16 | — | — | WO | disclosed |
| US-5994391-A | HYPERLIPEMIC AGENTS; ANTICHOLESTEROL AGENTS | G.D. SEARLE AND COMPANY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0888333-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997033882-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE AND CO. (US) | 1997-09-18 | — | — | WO | disclosed |
| EP-0781278-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO COMPANY (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008484-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO COMPANY (US) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624111-B2 | Methods for treating metastatic colon cancer with leronlimab | CCR5, CCL2, CCR2 | GPR3 534/4885CA1 3319/4885CA2 4023/4885 |
| US-20060062862-A1 | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances | CETP, HMGCR, PCSK9 | GPR3 4144/4885CA1 3188/4885CA2 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.